Clinical trials: NSCLC Stage II
Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes.
- Conditions
- Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03735095
- Testing
- Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Cancer
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Preclinical data in lung cancer cell lines showed that EGFR mutation can potentially be a positive predictor for sensitivity to BKM120.
- Trial name
- NCT01487265
- Testing
- BKM120 and Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small-Cell Lung Carcinoma
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment.
- Trial name
- NCT01801111
- Testing
- Erlotinib, Alectinib
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Non-small-cell Lung Cancer
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two prior lines of chemotherapy.
- Trial name
- NCT01124864
- Testing
- AUY922
- Where
- 22 sites in United States, Canada and 8 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01935336
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Colorado, Denver
Carcinoma, Non Small Cell Lung
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second…
- Trial name
- NCT01671332
- Testing
- Docetaxel, Suramin
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Wisconsin, Madison
Non Small Cell Lung Cancer
Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR).
- Trial name
- SABR (NCT02262000)
- Testing
- Image Guided Stereotactic Ablative Radiotherapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- West Virginia University
Non Small Cell Lung Cancer (NSCLC)
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy.
- Trial name
- NCT01905657
- Testing
- Pembrolizumab, Docetaxel
- Volunteers
- 1,034 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Sunitinib Non Small Cell Lung Cancer Patients Over 70
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
- Trial name
- NCT00864721
- Testing
- Sutent
- Where
- 13 sites in United States
- Volunteers
- 63 people
- Sponsor
- US Oncology Research
Non Small Cell Lung Cancer
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an…
- Trial name
- ZELIG (NCT00753714)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small Cell Lung
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
- Trial name
- NCT00281021
- Testing
- Erlotinib plus Digoxin
- Volunteers
- 26 people
- Sponsor
- University of Louisville
Non Small Cell Lung Cancer, Lung Cancer
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy.
- Trial name
- FLT3 (NCT04491084)
- Testing
- FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Albert Einstein College of Medicine
Non-small Cell Lung Cancer Metastatic
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Response rates. Changes in tumor blood flow.
- Trial name
- NA_00067809 (NCT01752023)
- Testing
- Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain (brain metastases).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT02971501
- Testing
- Bevacizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 18 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00792701
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 147 sites in United States
- Volunteers
- 85 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of budesonide may keep lung cancer from forming in patients with lung nodules.
- Trial name
- NCT00321893
- Testing
- Budesonide
- Where
- Italy
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
ALK Gene Translocation, EGFR Activating Mutation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of plinabulin when given together with nivolumab and to see how well they work in treating patients with stage IIIB-IV non-small cell lung cancer that has come back or…
- Conditions
- ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation
- Trial name
- NCT02846792
- Testing
- Nivolumab, Plinabulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells.
- Trial name
- NCT00389805
- Testing
- bortezomib, pemetrexed disodium, gene expression analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Non-small Cell Lung Cancer, Brain Cancer
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung…
- Trial name
- NCT00871923
- Testing
- Tarceva (Erlotinib hydrochloride), Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline